Rothschild Capital Partners LLC lowered its position in Nektar Therapeutics (NASDAQ:NKTR) by 7.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 55,451 shares of the biopharmaceutical company’s stock after selling 4,404 shares during the period. Rothschild Capital Partners LLC’s holdings in Nektar Therapeutics were worth $1,331,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. BlackRock Inc. raised its stake in shares of Nektar Therapeutics by 0.9% in the second quarter. BlackRock Inc. now owns 20,221,479 shares of the biopharmaceutical company’s stock worth $395,330,000 after purchasing an additional 185,933 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Nektar Therapeutics by 3.0% in the second quarter. Vanguard Group Inc. now owns 14,009,894 shares of the biopharmaceutical company’s stock worth $273,893,000 after purchasing an additional 401,914 shares during the last quarter. State Street Corp raised its stake in shares of Nektar Therapeutics by 11.3% in the second quarter. State Street Corp now owns 4,408,270 shares of the biopharmaceutical company’s stock worth $86,179,000 after purchasing an additional 447,023 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Nektar Therapeutics by 0.6% in the second quarter. Bank of New York Mellon Corp now owns 2,138,632 shares of the biopharmaceutical company’s stock worth $41,812,000 after purchasing an additional 12,730 shares during the last quarter. Finally, FMR LLC raised its stake in shares of Nektar Therapeutics by 42.4% in the first quarter. FMR LLC now owns 1,947,644 shares of the biopharmaceutical company’s stock worth $45,711,000 after purchasing an additional 580,341 shares during the last quarter. Institutional investors and hedge funds own 95.13% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was first reported by Watch List News and is owned by of Watch List News. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.watchlistnews.com/rothschild-capital-partners-llc-sells-4404-shares-of-nektar-therapeutics-nktr/1676141.html.

Several analysts have recently commented on NKTR shares. HC Wainwright started coverage on Nektar Therapeutics in a research note on Monday, August 7th. They issued a “buy” rating and a $31.00 price objective for the company. BidaskClub raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. Jefferies Group LLC reissued a “buy” rating and issued a $23.00 price objective on shares of Nektar Therapeutics in a research note on Friday, August 18th. Mizuho started coverage on Nektar Therapeutics in a research note on Tuesday, September 26th. They issued a “buy” rating and a $30.00 price objective for the company. Finally, ValuEngine raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the stock. Nektar Therapeutics has a consensus rating of “Buy” and a consensus target price of $26.80.

In related news, SVP Stephen K. Doberstein sold 1,701 shares of the company’s stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $19.32, for a total value of $32,863.32. Following the transaction, the senior vice president now directly owns 31,102 shares of the company’s stock, valued at approximately $600,890.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Roy A. Whitfield acquired 35,000 shares of the stock in a transaction that occurred on Thursday, August 10th. The stock was acquired at an average cost of $17.95 per share, for a total transaction of $628,250.00. Following the completion of the transaction, the director now directly owns 133,000 shares in the company, valued at approximately $2,387,350. The disclosure for this purchase can be found here. Insiders sold a total of 539,983 shares of company stock worth $12,388,528 over the last ninety days. 6.10% of the stock is currently owned by insiders.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.04). The business had revenue of $34.60 million during the quarter, compared to the consensus estimate of $33.64 million. Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. The business’s revenue was up 5.5% compared to the same quarter last year. During the same period last year, the company posted ($0.36) earnings per share.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.